Biolegend, 640932, APC Annexin V Apoptosis Detection Kit with PI
100tests
Catalog Number: 640932
Send an RFQ.
Category
| Verified Reactivity | Human, Mouse, Rat |
|---|---|
| Reported Reactivity | Other Species |
| Concentration | Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.) |
| Storage & Handling | Store between 2°C and 8°C. Do not freeze.Caution: Propidium Iodide Solution is toxigenic and mutagenic; handle with care. |
| Application | FC - Quality tested |
| Excitation Laser | Red Laser (633 nm) |
| Application Notes | Annexin V Staining Wash cells twice with cold BioLegend Cell Staining Buffer (Cat. No. 420201) and then resuspend the desired amount of cells in Annexin V Binding Buffer (Cat. No. 422201) at a concentration of 0.25-1.0 x 107 cells/mL Transfer 100 µL of cell suspension in 5 mL test tube. Add 5 µL of fluorochrome conjugated Annexin V. Stain with a viability dye, such as PI (Cat. No. 421301), 7-AAD (Cat. Nos. 420403 & 420404), or Helix NP dyes (Cat. Nos. 425301, 425303, & 425305), if desired. Gently vortex the cells and incubate for 15 min at RT (25°C) in the dark. Add 400* µL of Annexin V Binding Buffer (Cat. No. 422201) to each tube. *For more concentrated samples, add a minimum of 200 µl of Annexin V Binding Buffer in this step. Analyze by flow cytometry. For a better experience detecting apoptosis, we now recommend Apotracker™. Cell staining with Apotracker™ is Calcium independent. Thus, no special buffers are required, and the protocol can be shortened for single-step co-staining with other reagents. |
Unless otherwise stated, the minimum order amount is USD 1,000.
For orders below USD 1,000, an additional handling fee may apply, or we may arrange local delivery / local handover where available.
All quotations are subject to final confirmation, including product availability, lead time, batch information, shipping cost, and applicable export or handling requirements.
For quotation requests, please send an RFQ from website or contact:
Please send inquiries directly to us in the “To” field. Emails sent via BCC, mass mailing, or with unrelated recipients may be automatically filtered and will not be processed.
| Application References(PubMed link indicates BioLegend citation) | Ranganathan P, et al. 2014. J AM Soc Nephrol. 25:239. PubMed Bernhart E, et al. 2014. Neuro Onco. 16:933. PubMed |
|---|
| Product Citations | Zhou L, et al. 2020. Oxid Med Cell Longev. 2685310:2020. PubMed Shrestha C,et al. 2017. PLoS One. 10.1371/journal.pone.0186169. PubMed Grubb T, et al. 2022. Clin Cancer Res. 28:4689. PubMed Lampron MC, et al. 2023. Cells. 12:. PubMed Lee J, et al. 2023. Front Cell Dev Biol. 11:1144110. PubMed Yakovlev VA, et al. 2023. Front Oncol. 13:1124147. PubMed Chaturvedi S, et al. 2023. Cell. 186:2036. PubMed Cui Y, et al. 2023. Research (Wash D C). 6:0162. PubMed Ke C, et al. 2022. Cell Biol Int. 46:579. PubMed Del Rosario RCH, et al. 2022. Nat Microbiol. 7:312. PubMed Pal D, et al. 2022. Cell Rep Med. 3:100717. PubMed Gutierrez WR, et al. 2022. JCI Insight. 7: . PubMed Li W, et al. 2023. Immunol Cell Biol. 101:78. PubMed Guo F, et al. 2023. Am J Reprod Immunol. 89:e13663. PubMed Gong Z, et al. 2023. Exp Hematol Oncol. 12:7. PubMed Gao LT, et al. 2023. Cell Mol Life Sci. 80:58. PubMed Li X, et al. 2023. J Transl Med. 21:121. PubMed Bikorimana JP, et al. 2022. iScience. 25:105537. PubMed Rodrigues M, et al. 2022. Biochem J. 479:1891. PubMed Chaturvedi S, et al. 2022. Cell. 185:2086. PubMed Baldominos P, et al. 2022. STAR Protoc. 3:101795. PubMed Wang H, et al. 2020. Onco Targets Ther. 13:3903. PubMed O'Connor CM, et al. 2022. Cancer Res. 82:721. PubMed Blackburn CMR, et al. 2021. Atherosclerosis. 330:76. PubMed Azad P, et al. 2022. Exp Mol Med. :. PubMed Vitali E, et al. 2020. Cancers (Basel). 12:00. PubMed Daza–Cajigal V, et al. 2019. Front Immunol. 10:2065. PubMed Cremasco F, et al. 2021. PLoS One. 16:e0241091. PubMed Wang F, et al. 2021. J Exp Clin Cancer Res. 40:259. PubMed Sun X, et al. 2022. JCI Insight. 7: . PubMed Lv ZY, et al. 2022. J Inflamm Res. 15:2819. PubMed Dichtl S, et al. 2021. Sci Adv. 7: . PubMed Cousin N, et al. 2021. Cancer Res. 81:4133. PubMed Liu K, et al. 2021. Front Cell Dev Biol. 9:678209. PubMed Zou J, et al. 2015. PLoS One. 10: 0136843. PubMed Portman N, et al. 2020. Breast Cancer Res. 0.977083333. PubMed Wang Z, et al. 2017. Elife. 6:e30590. PubMed Wang J, et al. 2021. Int J Mol Med. 47:643. PubMed Yetkin D, et al. 2021. EXCLI J. 20:1394. PubMed Takahashi H, et al. 2019. Sci Rep. 1.136111111. PubMed Daza-Cajigal V, et al. 2022. Front Immunol. 13:888427. PubMed Li T, et al. 2021. Front Cell Dev Biol. 9:599020. PubMed Qi T, et al. 2022. Invest Ophthalmol Vis Sci. 63:11. PubMed Zhang Y, et al. 2021. Cell Death Discov. 7:192. PubMed Gomzikova MO, et al. 2020. Sci Rep. 10:10740. PubMed Nassa G, et al. 2019. Sci Adv. 5:eaav5590. PubMed Karagül MI, et al. 2020. EXCLI J. 19:532. PubMed Liu C, et al. 2021. Immun Inflamm Dis. 9:1749. PubMed Bernhart E, et al. 2014. Neuro Oncology. 16:933. PubMed Deventhiran J, et al. 2016. J Virol. 90: 222 - 231. PubMed He L, et al. 2021. Front Physiol. 12:664222. PubMed Yan Y, et al. 2021. Br J Cancer. 125:101. PubMed Zhang N, et al. 2021. Atherosclerosis. 334:39. PubMed Quintanal-Villalonga A, et al. 2022. Cancer Res. 82:472. PubMed Li Y, et al. 2020. Nat Cancer. 1:882. PubMed Gong Y, et al. 2020. J Neuroinflammation. 0.845833333. PubMed Zhang S, et al. 2021. Cell Death Discov. 49:7. PubMed Xu P, et al. 2020. Cancer Immunol Res. 8:1193. PubMed Lyu X, et al. 2022. Discov Oncol. 13:30. PubMed Harro CM, et al. 2020. J Clin Invest. . PubMed Gantenbein N, et al. 2018. Eur J Cancer. 101:165. PubMed González-Rodríguez P, et al. 2022. Cell Death Dis. 13:953. PubMed Lohberger B, et al. 2016. PLoS One. 11:e0168193. PubMed Przystupski D, et al. 2019. Front Pharmacol. 10:851. PubMed Dudek M, et al. 2021. Nature. 592:444. PubMed Javellana M, et al. 2022. Cancer Res. 82:169. PubMed Wang YM, et al. 2022. Oncoimmunology. 11:2034257. PubMed Surya R, et al. 2016. Carcinogenesis. 37: 635 - 645. PubMed Hu X, et al. 2020. Neoplasia. 1.290972222. PubMed Pogozhykh D, et al. 2017. Stem Cell Res Ther. 10.1186/s13287-017-0512-7. PubMed Widodo N, et al. 2022. F1000Res. 11:169. PubMed He S, et al. 2022. Ren Fail. 44:171. PubMed Baxley RM, et al. 2021. Nat Commun. 1626:12. PubMed Schnoor B, et al. 2022. Front Bioeng Biotechnol. 10:941817. PubMed Morretton JP, et al. 2022. EMBO Mol Med. 14:e15670. PubMed |
|---|
| Biology Area | Apoptosis/Tumor Suppressors/Cell Death, Cell Biology, Cell Proliferation and Viability, Neuroscience |
|---|
| Gene ID | 308 |
|---|
| Regulatory Status | RUO |
|---|
| Other Names | Annexin A5 Apoptosis Detection Kit, Dead, Apoptosis |
|---|